Evidence map›Paper›PMID 38357778›Full record

Trial reportJournal of the European Academy of Dermatology and Venereology : JEADV2024

Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis.

Julie Ryan Wolf, Anita Chen, Jill Wieser, Brad Johnson, Lauren Baughman, Gayin Lee, Eleanor Pope, Abigail Franco, Tanzy Love, Lisa A Beck

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the European Academy of Dermatology and Venereology : JEADV, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Julie Ryan WolfDepartment of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.ORCID https://orcid.org/0000-0002-0592-7820
Anita ChenDepartment of Biostatistics & Computational Biology, University of Rochester Medical Center, Rochester, New York, USA.
Jill WieserDepartment of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.
Brad JohnsonDepartment of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.
Lauren BaughmanDepartment of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.
Gayin LeeDepartment of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.
Eleanor PopeDepartment of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.
Abigail FrancoDepartment of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.
Tanzy LoveDepartment of Biostatistics & Computational Biology, University of Rochester Medical Center, Rochester, New York, USA.
Lisa A BeckDepartment of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.ORCID https://orcid.org/0000-0002-8452-667X
University of Rochester Medical Center · US

Funding

VISUAL INDICES OF NEUROTOXICITYP30ES001247 · NIEHS · UNIVERSITY OF ROCHESTER · PI Sally W Thurston · 1985 to 2026
$42.8M
The University of Rochester's Clinical and Translational Science InstituteUL1TR002001 · NCATS · UNIVERSITY OF ROCHESTER · PI WILSON, KAREN M., ZAND, MARTIN S · 2016 to 2024
$34.6M
NCATS NIH HHS UL1 TR002001NIEHS NIH HHS P30 ES001247Pfizer 53234087
6 · The paper itself

Abstract

backgroundAtopic dermatitis (AD) is a chronic skin disease that affects 20% of children worldwide and is associated with low patient-reported quality of life (QoL). Crisaborole (CRIS) and tacrolimus 0.03% (TAC) are Food and Drug Administration (FDA)-approved topical treatments for mild to moderate AD with similar clinical efficacy. Utilization of patient-reported outcomes (PROs) may provide meaningful data on the impact of AD treatments on patients and caregivers. This study used PROs to monitor the impact of crisaborole (CRIS) and tacrolimus 0.03% (TAC) on children with mild/moderate atopic dermatitis (AD) and caregiver burden.

methodsThis open-label study randomized 47 child-caregiver dyads to CRIS or TAC for 12 weeks. Disease severity, child quality of life (QoL), itch, pain interference, anxiety, depression, sleep, caregiver burden and caregiver QoL were assessed at baseline, 6 and 12 weeks.

resultsA total of 36 dyads completed the study. Children (mean age = 8.0 ± 3.9 years) had mild baseline AD and were diverse by race (39% white; 36% Black) and gender (53% males). Caregivers were mostly female (78%; mean age = 37 ± 7.6 years). Both arms improved disease severity (Eczema Area and Severity Index) from baseline to 12 weeks (CRIS = -2.4 vs. TAC = -1.9). Within-arm analyses comparing baseline to 12 weeks revealed TAC, but not CRIS, improved all child and caregiver PROs except sleep (all p < 0.05).

conclusionsOur results demonstrated that topical treatment for 12 weeks was more beneficial than 6 weeks, with TAC improving more PROs than CRIS. Future trials should implement PROs to fully understand the impact of AD treatments.

Indexed as

Boron CompoundsBridged Bicyclo Compounds, HeterocyclicCaregiversDermatitis, AtopicPatient Reported Outcome MeasuresQuality of LifeTacrolimusAdolescentAnxietyChildChild, PreschoolDepressionFemaleHumansImmunosuppressive AgentsMaleBoron CompoundsBridged Bicyclo Compounds, HeterocycliccrisaboroleImmunosuppressive AgentsTacrolimus

Identifiers

PMID38357778
PMCPMC11209823
OpenAlexW4391843067

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.